Bulevirtide

6 trials 4 recruiting JAnti-infectives Orphan designation

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

4 Recruiting

2 Completed trials

4 Sponsors

11 Countries

Phase III

Phase II/III

Phase II

Phase III/IV

Phase IV

Phase III: 2 Phase II/III: 1 Phase II: 1 Phase III/IV: 1 Phase IV: 1

Indications tested

Sponsors using this IMP

Bluejay Therapeutics Inc. 2 Vir Biotechnology Inc. 2 Gilead Sciences Inc. 1 Karolinska University Hospital 1

All trials

6 total

Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting

2025-522015-42-00 Phase II/III 7 countries Bluejay Therapeutics Inc.
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta I… Recruiting

2024-517167-23-00 Phase III 8 countries Bluejay Therapeutics Inc.
A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide Recruiting

2024-519282-22-00 Phase III 6 countries Vir Biotechnology Inc.
Observational Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Patients with Chronic hepatitis D Recruiting

2023-504414-29-00 Phase III/IV 1 country Karolinska University Hospital
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended

2024-520062-54-00 Phase II 8 countries Vir Biotechnology Inc.
A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended

2022-501901-10-00 Phase IV 7 countries Gilead Sciences Inc.

Showing 1–6 of 6 trials

← All drugs A–Z